Cargando…

Stability of the pneumococcal population structure in Massachusetts as PCV13 was introduced

BACKGROUND: The success of 7-valent pneumococcal conjugate vaccination (PCV-7) introduced to the US childhood immunization schedule in 2000 was partially offset by increases in invasive pneumococcal disease (IPD) and pneumococcal carriage due to non-vaccine serotypes, in particular 19A, in the years...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Qiuzhi, Stevenson, Abbie E, Croucher, Nicholas J, Lee, Grace M, Pelton, Stephen I, Lipsitch, Marc, Finkelstein, Jonathan A, Hanage, William P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336693/ https://www.ncbi.nlm.nih.gov/pubmed/25887323 http://dx.doi.org/10.1186/s12879-015-0797-z

Ejemplares similares

Population genomics of pneumococcal carriage in Massachusetts children following introduction of PCV-13
por: Mitchell, Patrick K., et al.
Publicado: (2019)

Impact of PCV13 on Serotype 3 Invasive Pneumococcal Disease and Nasopharyngeal Carriage in Massachusetts’ Children
por: Lapidot, Rotem, et al.
Publicado: (2017)

Population genomics of post-vaccine changes in pneumococcal epidemiology
por: Croucher, Nicholas J., et al.
Publicado: (2013)

Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts
por: Lapidot, Rotem, et al.
Publicado: (2020)

Selective and Genetic Constraints on Pneumococcal Serotype Switching
por: Croucher, Nicholas J., et al.
Publicado: (2015)

Epidemiology and risk factors for Staphylococcus aureus colonization in children in the post-PCV7 era
por: Lee, Grace M, et al.
Publicado: (2009)

Population genomic datasets describing the post-vaccine evolutionary epidemiology of Streptococcus pneumoniae
por: Croucher, Nicholas J., et al.
Publicado: (2015)

Identification of pneumococcal colonization determinants in the stringent response pathway facilitated by genomic diversity
por: Li, Yuan, et al.
Publicado: (2015)

Decline in Pneumococcal Disease Attenuated in Older Adults and Those With Comorbidities Following Universal Childhood PCV13 Immunization
por: Pelton, Stephen I, et al.
Publicado: (2019)

Frequency-dependent selection in vaccine-associated pneumococcal population dynamics
por: Corander, Jukka, et al.
Publicado: (2017)

Excess Risk of Invasive Pneumococcal Disease (IPD) Persists in Adults with Comorbid Conditions in the Era of PCV13 Childhood and Adult Immunization
por: Pelton, Stephen I, et al.
Publicado: (2017)

Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden
por: Galanis, Ilias, et al.
Publicado: (2016)

597 Increase in IPD incidence in Adults in 2013-2014 after 2 consecutive years of decline following introduction of 13-valent pneumococcal conjugate vaccine (PCV13)
por: Baxter, Roger, et al.
Publicado: (2014)

Effect on nasopharyngeal pneumococcal carriage of replacing PCV7 with PCV13 in the Expanded Programme of Immunization in The Gambia
por: Roca, Anna, et al.
Publicado: (2015)

2703. Pneumococcal Carriage of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Non-PCV13 Serotypes among Greek Children Vaccinated with PCV13 in a 3 + 1 Schedule During the First 6 years after the Fourth Dose of PCV13
por: Syrogiannopoulos, George A, et al.
Publicado: (2019)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
por: Perdrizet, Johnna, et al.
Publicado: (2020)

1180. Comparing Changes in Pneumococcal Meningitis Incidence to all Invasive Pneumococcal Disease Following Introduction of PCV10 and PCV13: The PSERENADE Project
por: Yang, Yangyupei, et al.
Publicado: (2021)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
por: Ansaldi, Filippo, et al.
Publicado: (2020)

Effectiveness of 13-pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease in children in the Dominican Republic
por: Tomczyk, Sara, et al.
Publicado: (2018)

Population genomics of pneumococcal carriage in South Africa following the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) immunization
por: Javaid, Nida, et al.
Publicado: (2022)

Pneumococcal Meningitis in Adults after Introduction of PCV7 and PCV13, Israel, July 2009–June 2015
por: Regev-Yochay, Gili, et al.
Publicado: (2018)

Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany
por: van der Linden, Mark, et al.
Publicado: (2016)

Pneumococcal serotypes in children, clinical presentation and antimicrobial susceptibility in the PCV13 era
por: Izquierdo, C., et al.
Publicado: (2020)

Potentiating pneumococcal glycoconjugate vaccine PCV13 with saponin adjuvant VSA-1
por: Kim, Hyunjung, et al.
Publicado: (2022)

Heterogeneity in the Frequency and Characteristics of Homologous Recombination in Pneumococcal Evolution
por: Mostowy, Rafal, et al.
Publicado: (2014)

1735. Impact of Children Universal Pneumococcal Vaccination (PCV7v/PCV13v) on Pneumococcal Invasive Disease Hospitalizations in a Private General Hospital, Uruguay
por: Sanchez-Varela, Mercecedes, et al.
Publicado: (2023)

Nasopharyngeal Pneumococcal Carriage among Healthy Children in Cyprus Post Widespread Simultaneous Implementation of PCV10 and PCV13 Vaccines
por: Hadjipanayis, Adamos, et al.
Publicado: (2016)

1404. Twenty-year impact of Pneumococcal Conjugate Vaccines (PCV) on the burden of invasive pneumococcal disease in US children less than 5 years of age
por: Lapidot, Rotem, et al.
Publicado: (2020)

1480. Incidence of Non-Invasive Pneumococcal Pneumonia in Children in the United States before and after Introduction Pneumococcal Conjugate Vaccines (PCV7 and PCV13) during 1998-2018
por: Hu, Tianyan, et al.
Publicado: (2020)

A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly
por: Dirmesropian, S, et al.
Publicado: (2015)

1441. Doses of 13-Valent Conjugated Pneumococcal Vaccine (PCV13) for Patients With Multiple Myeloma (MM)
por: Sun, Hsin-Yun, et al.
Publicado: (2018)

Invasiveness potential of pneumococcal serotypes in children after introduction of PCV13 in Blantyre, Malawi
por: Kirolos, Amir, et al.
Publicado: (2023)

1430. Evolving Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease
por: Yildirim, Inci, et al.
Publicado: (2018)

Response to article by Johnna Perdrizet et al.,“Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants”
por: Gómez, Jorge A., et al.
Publicado: (2021)

Antibiotics in agriculture and the risk to human health: how worried should we be?
por: Chang, Qiuzhi, et al.
Publicado: (2015)

Direct and Indirect Impact of 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Invasive Pneumococcal Disease (IPD) Among Children and Adults in the U.S.
por: Pilishvili, Tamara, et al.
Publicado: (2017)

Panproteome-wide analysis of antibody responses to whole cell pneumococcal vaccination
por: Campo, Joseph J, et al.
Publicado: (2018)

How nasopharyngeal pneumococcal carriage evolved during and after a PCV13-to-PCV10 vaccination programme switch in Belgium, 2016 to 2018
por: Wouters, Ine, et al.
Publicado: (2020)

1173. Changes in Invasive Pneumococcal Disease Incidence Following Introduction of PCV10 and PCV13 Among Children < 5 Years: The PSERENADE Project
por: Bennett, Julia C, et al.
Publicado: (2021)

Estimating the Clinical and Economic Impact of Maintaining use of 13-valent Pneumococcal Conjugate Vaccine (PCV13) in Mexico
por: Wasserman, Matt, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_c6fesgn3a5nh586hrooms3dbvb